Hypertension

Active Ingredient: Candesartan

Indication for Candesartan

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Therapeutic intent: Curative procedure

For this indication, competent medicine agencies globally authorize below treatments:

4 mg once daily and thereafter 4-8 mg once daily for patients weighting <50 kg and 4-16 mg once daily for patients weighting ≥50 kg

For:

Dosage regimens

Regimen A: In case that patient weight is ≤ 50 kg, oral, 4 milligrams candesartan, once daily. Afterwards, in case that patient weight is ≤ 50 kg, oral, between 4 milligrams candesartan and 8 milligrams candesartan, once daily.

Regimen B: In case that patient weight is ≥ 50 kg, oral, 4 milligrams candesartan, once daily. Afterwards, in case that patient weight is ≥ 50 kg, oral, between 4 milligrams candesartan and 16 milligrams candesartan, once daily.

Detailed description

Children and adolescents aged 6 to <18 years

The recommended starting dose is 4 mg once daily.

  • For patients weighing <50 kg: In patients whose blood pressure is not adequately controlled, the dose can be increased to a maximum of 8 mg once daily.
  • For patients weighing ≥50 kg: In patients whose blood pressure is not adequately controlled, the dose can be increased to 8 mg once daily and then to 16 mg once daily if needed.

Doses above 32 mg have not been studied in paediatric patients.

Most of the antihypertensive effect is attained within 4 weeks.

For children with possible intravascular volume depletion (e.g., patients treated with diuretics, particularly those with impaired renal function), candesartan treatment should be initiated under close medical supervision and a lower starting dose than the general starting dose above should be considered.

Candesartan has not been studied in children with glomerular filtration rate less than 30 ml/min/1.73m².

Black paediatric patients

The antihypertensive effect of candesartan is less pronounced in black patients than in nonblack patients.

Children aged below 1 year to <6 years

  • The safety and efficacy in children aged 1 to <6 years of age has not been established. No recommendation on a posology can be made.
  • Candesartan is contraindicated in children aged below 1 year.

Dosage considerations

Candesartan should be taken once daily with or without food.

The bioavailability of candesartan is not affected by food.

Active ingredient

Candesartan

Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.

Read more about Candesartan

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.